Dr. Ahmad Doroudian on the Potential of a COVID-19 Treatment, Not a Cure | #HashtagFinance
The CSE’s Barrington Miller chats with Dr. Ahmad Doroudian, CEO of BetterLife Pharma Inc. (CSE:BETR), about BetterLife’s ambitions to advance on the AP-003 clinical trial programs of Altum Pharmaceuticals Inc., which includes a therapeutic pipeline consisting of three products, including AP-003, a patent-pending interferon a2b (IFNa2b) inhalation formulation. Recent studies in China and the UK have provided data that suggest the therapeutic efficacy of interferon-based treatments for COVID-19.
Here’s an overview of what’s covered in this edition of the #HashtagFinance podcast:
3:47 – What BetterLife is doing about COVID-19.
7:01 – How early their product can be used, and if it can be used for prevention.
9:32 – What BetterLife was working on before the COVID-19 pandemic.
11:32 – The differentiators between BetterLife and other companies developing COVID-19 treatments.
15:38 – Taking the treatment approach, instead of the cure approach, to COVID-19, similar to HIV.
19:58 – Phase II clinical trials, and what that means for an investor.
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. Through its wholly owned subsidiary, BLife Therapeutics Inc., BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.
Related links:
https://thecse.com/en/listings/life-sciences/betterlife-pharma-inc